CRISPR Therapeutics AG Insider Trading for August 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in CRISPR Therapeutics AG.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in CRISPR Therapeutics AG for August 2017.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Option Exercise | M | 1.81 | 5,722 | 10,357 | 44,679 | |
Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Option Exercise | M | 1.81 | 17,692 | 32,023 | 50,401 | |
Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Sell | S | 20.31 | 58,103 | 1,179,950 | 1,162,624 | 1.2 M to 1.2 M (-4.76 %) |
Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Buy | M | 1.81 | 5,722 | 10,357 | 1,220,727 | 1.2 M to 1.2 M (+0.47 %) |
Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Sell | S | 20.06 | 17,692 | 354,919 | 1,215,005 | 1.2 M to 1.2 M (-1.44 %) |
Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Buy | M | 1.81 | 17,692 | 32,023 | 1,232,697 | 1.2 M to 1.2 M (+1.46 %) |
Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 20.00 | 4,000 | 80,000 | 106,893 | 110.9 K to 106.9 K (-3.61 %) |
Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 20.09 | 23,154 | 465,162 | 110,893 | 134 K to 110.9 K (-17.27 %) |
Aug 30 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 19.79 | 88,011 | 1,741,738 | 1,951,359 | 2 M to 2 M (-4.32 %) |
Aug 28 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 19.52 | 14,913 | 291,102 | 2,039,370 | 2.1 M to 2 M (-0.73 %) |
Aug 28 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 19.23 | 7,868 | 151,302 | 2,054,283 | 2.1 M to 2.1 M (-0.38 %) |
Aug 24 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 18.53 | 7,035 | 130,359 | 2,062,151 | 2.1 M to 2.1 M (-0.34 %) |
Aug 24 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 18.53 | 10,954 | 202,978 | 2,069,186 | 2.1 M to 2.1 M (-0.53 %) |
Aug 22 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 18.51 | 1,250 | 23,138 | 2,080,140 | 2.1 M to 2.1 M (-0.06 %) |
Aug 22 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 18.53 | 1,900 | 35,207 | 2,081,390 | 2.1 M to 2.1 M (-0.09 %) |
Aug 18 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 18.74 | 13,593 | 254,733 | 2,083,290 | 2.1 M to 2.1 M (-0.65 %) |
Aug 18 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 19.27 | 20,548 | 395,960 | 2,096,883 | 2.1 M to 2.1 M (-0.97 %) |
Aug 16 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 19.53 | 25,586 | 499,695 | 2,117,431 | 2.1 M to 2.1 M (-1.19 %) |
Aug 16 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 19.64 | 29,983 | 588,866 | 2,143,017 | 2.2 M to 2.1 M (-1.38 %) |
Aug 09 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 18.71 | 19,850 | 371,394 | 2,190,872 | 2.2 M to 2.2 M (-0.90 %) |
Aug 09 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 18.53 | 15,623 | 289,494 | 2,210,722 | 2.2 M to 2.2 M (-0.70 %) |
Aug 08 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 18.60 | 1,313 | 24,422 | 153,204 | 154.5 K to 153.2 K (-0.85 %) |
Aug 08 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 18.56 | 13,210 | 245,209 | 154,517 | 167.7 K to 154.5 K (-7.88 %) |
Aug 08 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 18.55 | 477 | 8,848 | 167,727 | 168.2 K to 167.7 K (-0.28 %) |
Aug 07 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 18.50 | 3,068 | 56,758 | 2,226,345 | 2.2 M to 2.2 M (-0.14 %) |
Aug 07 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 17.77 | 47,409 | 842,458 | 2,229,413 | 2.3 M to 2.2 M (-2.08 %) |
Aug 02 2017 | CRSP | CRISPR Therapeutic ... | Ho Tony W | See Remarks | Option Exercise | A | 16.90 | 260,000 | 4,394,000 | 260,000 | |
Aug 02 2017 | CRSP | CRISPR Therapeutic ... | Ho Tony W | See Remarks | Option Exercise | A | 0.00 | 75,000 | 0 | 75,000 | |
Aug 02 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 17.50 | 264 | 4,620 | 2,276,822 | 2.3 M to 2.3 M (-0.01 %) |
Aug 02 2017 | CRSP | CRISPR Therapeutic ... | EMSTER KURT VON | Director | Sell | S | 17.51 | 5,248 | 91,871 | 2,277,086 | 2.3 M to 2.3 M (-0.23 %) |